Log in to your IBTimes Account

close
ID
Password
  • Set your IBTimes.com Edition

GSK Submits Tykerb for Market Approval



By Henry Tyler
18 September 2006 @ 11:56 am ET

GlaxoSmithKine plc has announced today the submission of a New Drug Application to the United States Food and Drug Administration (FDA), for approval to market. Tykerb® (lapatinib ditosylate), in combination with Xeloda® (capecitabine).

The new compound is meant for the treatment of advanced metastatic HER2 (ErbB32) positive breast cancer in women who have received prior therapy, a statement read.

The FDA has already granted fast track status to the compound. To date Tykerb is an investigational drug and has yet to be given approval for marketing by any regulatory body.

Paolo Paoletti, M.D., Senior Vice President of the Oncology Medicine Development Center at GlaxoSmithKline said in a statement: “This filing is the result of many years of tremendous research and development work by the scientists at GSK. It is truly an outstanding milestone, especially for the many thousands of women who are facing the devastating effects of advanced breast cancer,”

This article is copyrighted by International Business Times.

    Click!
  • Rate this article:

Comments

Post Your Comment

*Name


advertisement
More Politics & Policy
Anti-G8 demonstrators clashed briefly with Italian police on Saturday in the first big protest ahead of next week's summit of the world's richest nations...
Search crews have located a large piece of debris from a Yemeni jet that crashed into the Indian Ocean off the Comoros islands last week and are working ...
U.N. chief Ban Ki-moon rebuked Myanmar's generals on Saturday for denying him a visit to see detained opposition leader Aung San Suu Kyi and said she sho...

Advertisement
Press Release Distribution - IBwire

Effective and Affordable Press Release Distribution Service

advertisement
 
IBTimes.com Web
Partners
International Business Times© 2009 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives